Effect of Q10 and N-acetyl Cysteine antioxidants on Acute Kidney Injury

Investigation the Effect of Q10 and N-acetyl Cysteine antioxidants on reducing the Incidence of Acute Kidney Injury in high risk Patients Admitted to PICU

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180801040661N1

Enrollment

Registered

2019-01-12

Start date

2018-12-22

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury disease. Acute kidney failure, unspecified

Interventions

Intervention 1: Intervention group: The first intervention group includes recipients of n-acetyl cysteine who will receive 8mg/kg/TDS NAC during admission time at PICU. Intervention 2: Intervention gr

Eligibility

Sex/Gender

All

Age

1 Months to 18 Years

Inclusion criteria

Inclusion criteria: Filling out the informed consents form by child parents No history of renal failure Getting minimum score number 10 from PRISM3 scoring table

Exclusion criteria

Exclusion criteria: Children who have had kidney failure before the study Use of drugs that have interference with the study Contribution in another study at a same time The presence of side effects caused by study drugs

Design outcomes

Primary

Measure	Time frame
The important outcome of the current survey is the effect of NAC and Q10 in prevention of AKI which is performed by measuring several factors such as urine volume, blood urea nitrogen, creatinine, hemoglobin, white blood cells, platelet, sodium, potassium, phosphor, calcium and magnesium elements, as well as consideration of glomerular filtration in the kidney. Timepoint: Patients in NAC group will receive 8mg/kg/TDS NAC and patients in Q10 will be treated with 3 mg/kg/day Q10 during admission time at PICU. Method of measurement: Blood urea , creatinine, hemoglobin, white blood cells, sodium, potassium, will be measured using ELISA method. AKI disease severity will be evaluated using RIFLE standard criterion.	—

Measure

Time frame

The important outcome of the current survey is the effect of NAC and Q10 in prevention of AKI which is performed by measuring several factors such as urine volume, blood urea nitrogen, creatinine, hemoglobin, white blood cells, platelet, sodium, potassium, phosphor, calcium and magnesium elements, as well as consideration of glomerular filtration in the kidney. Timepoint: Patients in NAC group will receive 8mg/kg/TDS NAC and patients in Q10 will be treated with 3 mg/kg/day Q10 during admission time at PICU. Method of measurement: Blood urea , creatinine, hemoglobin, white blood cells, sodium, potassium, will be measured using ELISA method. AKI disease severity will be evaluated using RIFLE standard criterion.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Sakhaei

Iran University of Medical Sciences

sakhaei.m@iums.ac.ir+98 21 2304 6253

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026